Suzanne de Waha1,2, Katharina Schoene3, Georg Fuernau4,5, Steffen Desch4,5,3, Ingo Eitel4,5, Janine Pöss4,5, Roza Meyer-Saraei4,5, Charlotte Eitel4,5, Roland Tilz4,5, Gerhard Schuler3, Karl Werdan6, Steffen Schneider7, Taoufik Ouarrak7, Uwe Zeymer7,8, Holger Thiele3. 1. University Heart Centre Luebeck, Department of Cardiology, Angiology, and Intensive Care Medicine, University Hospital Schleswig-Holstein, Ratzeburger Allee 160, 23538, Luebeck, Germany. s-dw@gmx.net. 2. German Centre for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Luebeck, Luebeck, Germany. s-dw@gmx.net. 3. Heart Centre Leipzig, Department of Internal Medicine-Cardiology, University of Leipzig, Leipzig, Germany. 4. University Heart Centre Luebeck, Department of Cardiology, Angiology, and Intensive Care Medicine, University Hospital Schleswig-Holstein, Ratzeburger Allee 160, 23538, Luebeck, Germany. 5. German Centre for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Luebeck, Luebeck, Germany. 6. Martin Luther University Halle-Wittenberg, Department of Cardiology and Angiology, Halle/Saale, Germany. 7. Institut für Herzinfarktforschung, Ludwigshafen, Germany. 8. Klinikum Ludwigshafen, Medical Clinic B, Ludwigshafen, Germany.
Abstract
BACKGROUND: Aim of the current study was to analyse the impact of atrial fibrillation (AF) on prognosis in patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI), which has never been investigated yet. METHODS: The current analysis is a substudy of the IABP-SHOCK II trial. Patients were grouped according to the presence or absence of AF. The primary endpoint was all-cause mortality at 30-day follow-up. Secondary endpoints included all-cause mortality, recurrent myocardial infarction, repeat revascularisation, and stroke at 12 months. RESULTS: AF was documented in 28.2% (n = 169) of all 600 patients initially enrolled in the IABP-SHOCK II trial. There were no significant differences with respect to mortality at 30 days and 12 months between patients with and without AF (p = 0.81, p = 0.74). Similarly, the rates of recurrent myocardial infarction, repeat revascularisation, and stroke did not differ between groups (all p > 0.05). There was no interaction of intraaortic balloon counterpulsation (IABP) and no IABP in patients with or without AF with respect to clinical outcome at 30 days and 12 months (p > 0.05). CONCLUSION: AF is not associated with clinical outcome at 30 days and 12 months in CS complicating AMI.
RCT Entities:
BACKGROUND: Aim of the current study was to analyse the impact of atrial fibrillation (AF) on prognosis in patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI), which has never been investigated yet. METHODS: The current analysis is a substudy of the IABP-SHOCK II trial. Patients were grouped according to the presence or absence of AF. The primary endpoint was all-cause mortality at 30-day follow-up. Secondary endpoints included all-cause mortality, recurrent myocardial infarction, repeat revascularisation, and stroke at 12 months. RESULTS:AF was documented in 28.2% (n = 169) of all 600 patients initially enrolled in the IABP-SHOCK II trial. There were no significant differences with respect to mortality at 30 days and 12 months between patients with and without AF (p = 0.81, p = 0.74). Similarly, the rates of recurrent myocardial infarction, repeat revascularisation, and stroke did not differ between groups (all p > 0.05). There was no interaction of intraaortic balloon counterpulsation (IABP) and no IABP in patients with or without AF with respect to clinical outcome at 30 days and 12 months (p > 0.05). CONCLUSION:AF is not associated with clinical outcome at 30 days and 12 months in CS complicating AMI.
Authors: S S Rathore; A K Berger; K P Weinfurt; K A Schulman; W J Oetgen; B J Gersh; A J Solomon Journal: Circulation Date: 2000-03-07 Impact factor: 29.690
Authors: Patricia Jabre; Véronique L Roger; Mohammad H Murad; Alanna M Chamberlain; Larry Prokop; Frédéric Adnet; Xavier Jouven Journal: Circulation Date: 2011-04-04 Impact factor: 29.690
Authors: Damien J LaPar; Alan M Speir; Ivan K Crosby; Edwin Fonner; Michael Brown; Jeffrey B Rich; Mohammed Quader; John A Kern; Irving L Kron; Gorav Ailawadi Journal: Ann Thorac Surg Date: 2014-08 Impact factor: 4.330
Authors: Casper N Bang; Gunnar H Gislason; Anders M Greve; Christian A Bang; Alexander Lilja; Christian Torp-Pedersen; Per K Andersen; Lars Køber; Richard B Devereux; Kristian Wachtell Journal: J Am Heart Assoc Date: 2014-01-21 Impact factor: 5.501
Authors: Bernhard Wernly; Clemens Seelmaier; David Leistner; Barbara E Stähli; Ingrid Pretsch; Michael Lichtenauer; Christian Jung; Uta C Hoppe; Ulf Landmesser; Holger Thiele; Alexander Lauten Journal: Clin Res Cardiol Date: 2019-03-21 Impact factor: 5.460
Authors: Saraschandra Vallabhajosyula; Sri Harsha Patlolla; Dhiran Verghese; Lina Ya'Qoub; Vinayak Kumar; Anna V Subramaniam; Wisit Cheungpasitporn; Pranathi R Sundaragiri; Peter A Noseworthy; Siva K Mulpuru; Malcolm R Bell; Bernard J Gersh; Abhishek J Deshmukh Journal: Am J Cardiol Date: 2020-04-06 Impact factor: 2.778